Abstract: Autoimmune manifestations are common in human immunodeficiency virus (HIV) patients. However, the autoantibody spectrum associated with HIV infection and the impact of antiretroviral therapy (ART) remains to be determined.
INTRODUCTION

I
ncreased prevalence and titer of circulating autoantibodies have been reported in patients infected with human immunodeficiency virus (HIV) type 1.
1 Up to 68.1% of HIV patients have circulating antinuclear antibodies (ANAs), [1] [2] [3] [4] including autoantibodies against cellular DNA, 1,3 small nuclear ribonucleoproteins (snRNPs), 1, 5 histone H2B, 6 Smith (Sm), 7 SSA (Ro), 8 and SSB (La). 8 In addition to ANAs, autoantibodies against peripheral blood cells, 7 MHC II, 7 and phospholipids 3, 7, 9 have also been frequently observed in HIV patients. The increased incidence and titer of autoantibodies are associated with lower CD4 þ T cell count and higher mortality in HIV patients who are naive to antiretroviral therapy (ART), 3 indicating that autoantibodies may play a pathogenic role or can serve as a prognostic indicator in HIV infection. In fact, autoimmune diseases including systemic lupus erythematosus (SLE), rheumatological syndromes, antiphospholipid syndrome, vasculitis, primary biliary cirrhosis, polymyositis, Graves' disease, and idiopathic thrombocytopenic purpura have been frequently reported in HIV/acquired immune deficiency syndrome (AIDS) patients. 1 Therefore, it is important to characterize the spectrum of emerging autoantibodies in HIV patients as this may shed light on resolving HIV infection related autoimmune manifestation.
Moreover, in the current era of ART, a plethora of concerns about autoimmune manifestations in HIV patients have been raised, which could determine the therapeutic efficiency. Therefore, further elucidating the impact of ART on autoantibody spectrum in HIV patients is important and valuable for therapeutic evaluation.
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Recently, immune regulatory cells, including regulatory T cells (Tregs, CD25
þ FoxP3 þ ) and myeloid-derived suppressor cells (MDSCs, CD33 þ CD11b þ HLA-DR À ), are widely observed to increase in frequency in HIV patients, which is thought to be responsible for the severe impaired cytotoxic T cell (CTL) immune response in vivo. [10] [11] [12] [13] [14] [15] [16] These immune regulatory cells play pivotal roles in the maintenance of selftolerance as well as control of immune activation, particularly during chronic infections. [17] [18] [19] [20] [21] [22] [23] In the setting of autoimmune manifestation caused by HIV infection, it also becomes crucial to know the roles of Tregs, MDSCs, and other immune cells in the development of an autoimmune response.
In the present study, we investigated autoantibody profiles in HIV patients who had maintained undetectable viral loads on long-term ART, HIV patients who were ART-naïve, and healthy subjects, and further explored the roles of immune regulatory cells on regulating the autoimmune response.
METHODS
Study Participants
The study was performed according to a protocol approved by the Institutional Review Boards for Human Research at the Indiana University School of Medicine (Indianapolis, IN). Written informed consent was obtained from each of all participants before blood collection. Three groups of individuals were recruited in this study: 20 healthy controls, 17 HIV-infected ART-naive individuals (CD4 cell counts: 422 cells/mm 3 , range 16-1237; viral load: 11,532 copies/mL, range 59-570,156 copies/mL), and 14 HIV-infected individuals on ART with undetectable viral load (<50 copies/mL) for at least 2 years (CD4 cell counts: 556 cells/mm 3 , range 231-1310). Peripheral blood from these participants was collected in BD Vacutainer tubes (containing 143 USP units of sodium heparin per 10-mL tube, BD, Franklin Lakes, NJ). These blood samples were separated into peripheral blood mononuclear cells (PBMCs) and plasma and stored at S80 8C or liquid nitrogen until use.
Autoantigen Protein Microarray
Circulating autoantibody profiles in plasma samples from uninfected and HIV-infected individuals were determined using an autoantigen protein microarray as previously described. 24, 25 The autoantigen protein microarray included 83 autoantigens and 4 control proteins and was performed in the Microarray Core Facility of the Texas University (Dallas, TX). Briefly, the plasma sample diluted at 1:100 was added to the arrays in duplicate. Net fluorescence intensities (NFIs) were generated by A Genepix 4000B scanner and Genepix Pro 6.0 software and normalized using anti-human IgG spotted onto each array. Values obtained from duplicate spots were averaged. Tests of significance between groups were carried out using a Student's t-test or one-way ANOVA for multiple groups (GraphPad Prism 5.02). Correlations between continuous variables were determined using Pearson r, and dichotomized variables were compared using Fisher exact test. A P value < 0.05 was considered significant. Diagrams with row-wise and column-wise clustering were generated using Cluster and Treeview software (http:// rana.lbl.gov/EisenSoftware.htm).
ELISA
An enzyme-linked immunosorbent assay (ELISA) was developed to confirm the microarray data and to titrate autoantibodies in plasma samples. Briefly, 96-well plates were coated with individual recombinant human autoantigens including centromere protein B (CENP-B), Intrinsic Factor, nuclear pore glycoprotein-210 (gp210), mitochondrial antibody subtype M2 (MA-M2), synthetase (PL7), proteins of the nucleolar PM/ Scl macromolecular complex (PM/Scl-75), SP100, signal recognition particle 54 kDa protein (SRP54), Lupus La protein or Sjögren syndrome type B antigen (La/SS-B), and small nucleoprotein particles (snRNPs) such as U1-snRNP-68, U1-snRNP-A, U1-snRNP-BB 0 , and U1-snRNP-C (SurModics, Eden Prairie, MN). After washing and blocking with 5% FBS/PBS, plates were incubated with serially diluted plasma, followed by the addition of goat anti-human IgG monoclonal antibody conjugated with horseradish peroxidase (HRP). Optical densities (OD) at 450 nm were determined using an ELISA plate reader (ELX 808 microplate reader, Winooski, VT). Results were expressed as titers. All ELISA reagents were purchased from SurModics (Eden Prairie, MN). The observed endpoint titer for the autoantibody assay was the highest plasma dilution that yielded an OD greater than the value that defined the cutoff between positive and negative results.
PBMC Preparation, Cell Depletion, and Sorting
PBMCs were isolated from whole blood by Ficoll centrifugation and analyzed immediately or cryopreserved at À80 8C. PBMCs were subjected to a positive selection of CD33 
HLA-DR
À by FACS using a BD FACSAria (BD Biosciences, San Jose, CA).
Flow Cytometric Analysis
Cell surface staining with antibodies conjugated with fluorochromes was performed as previously described. 26 The following anti-human antibodies conjugated with fluorochromes were purchased from eBiosciences (San Diego, CA): CD14-FITC, CD4-FITC, CD11b-PE, CD25-PE, CD3-PerCP, CD33-PercpCY5.5, HLA-DR-APC, FoxP3-APC, and isotype-matched control antibodies conjugated with fluorochrome. Intracellular staining (ICS) with anti-human FoxP3-PE was performed using the FoxP3 staining buffer set (eBiosciences, San Diego, CA) according to the manufacturer's instructions. As a heterogeneous cell population, human MDSCs could be further divided into 2 subsets, monocytic
. 12, 18, [20] [21] [22] [23] Given that G-MDSCs are unavailable in Ficoll-prepared PBMCs, we set the gating strategy for M-
Meanwhile, the gating strategy for Tregs was CD3
Cells were collected on a FACSCalibur (BD). The data were analyzed using FlowJo software (TreeStar, San Carlos, CA). Appropriate isotype controls were used at the same protein concentration as the test antibodies, and control staining was performed during every FACS.
B Cell ELISpot Assay
B cell ELISpot kit from MABTECH (Cincinnati, OH) was used to enumerate the number of autoantibody-secreting B cells based on the manufacturer's instructions. Briefly, 96-well plates with PVDF membrane were coated with 13 mixed autoantigens (4 mg/mL of each autoantigen) or anti-human IgG (15 mg/mL, MABTECH) after membrane activation with 70% ethanol. PBMCs or CD33 þ cell-depleted PBMCs from HIV patients or healthy donors were stimulated with R848 (1 ng/mL)/IL-2 (10 ng/mL), the CD33 þ cell-depleted PBMCs were cocultured with autologous sorted CD33 þ cells at various ratios (1:1, 1:5, 1:10) in 24-well plates for 3 days. After harvesting the supernatant from cultured cells, these cells were washed 3 times and transferred into 96-well PVDF plates at 2.5 Â 10 5 cells/well for overnight culturing. Reactions were visualized using alkaline phosphatase (AP)-conjugated Streptavidin (MABTECH) and BCIP/NBT substrate (MABTECH). The number of spots per 10 6 PBMCs, which represented the number of autoantibodyproducing B cells, was calculated by an ELISpot plate reader (Bio-Sys GmbH, Karben, Germany).
Statistical Analysis
Data were expressed as mean AE standard deviation (SD). Statistical differences were determined by paired Student's ttest for paired comparisons, one-way ANOVA with post-tests for multiple group comparisons and linear regression analysis for correlations using Prism 5.02 (Graphpad Software, La Jolla, CA). A P value less than 0.05 was considered to be significant. The data produced by the current ProtoArray platform were evaluated for the presence or absence of a significant signal, which is a commonly used approach for data analysis when using ELISA kits for autoantibody measurement. The significantly elevated antibodies were determined by P < 0.05 based on one-way ANOVA test among multiple groups.
RESULTS
Autoantibody Profiles Altered in HIV Patients
Eighty-three IgG autoantibody specificities across all plasma samples were measured via protein microarrays and analyzed using hierarchical clustering. Most clusters included antibodies which showed correlation to each other; 10 clusters could be distinguished from the IgG autoantibody heat map ( Figure 1 ). Based on the microarray profiling, 15 antibodies (including CENPB, chromatin, collagen I, H2A, Intrinsic Factor, gp210, M2, PL7, PM/Scl-75, SP100, SRP54, La/SS-B, SS-A/SS-B, U1-snRNP-68, and U1-snRNP-A) were significantly elevated (P < 0.05) in ART-naive HIV patients compared to healthy controls (Table 1) , which cluster together in clusters 2 and 7 ( Figure 1) . Eight of the 15 autoantibodies (including collagen I, gp210, H2A, Intrinsic Factor, M2, PL7, PM/Scl-75, and U1-snRNP-68) were also observed to be significantly elevated in the HIV patients on ART compared to those from healthy control subjects (cluster 7, Figure 1 and Table 1 ). When compared to HIV patients on ART, ART-naive HIV patients had 5 significantly elevated autoantibodies (gp210, H2A, SP100, PM/Scl75, and SRP54) ( Table 1) .
HIV Patients Had Higher Prevalence of Elevated Autoantibodies Than Healthy Controls
Mean NFIs of detecting autoantibody in healthy controls were set as cutoff values for evaluating the changes of autoantibodies: >2-fold cutoff as elevated autoantibody. Individually, HIV patients had a higher prevalence of elevated autoantibodies than healthy controls as indicated by the Heatmap (Figure 1 ). The number of elevated autoantibodies per sample ranged from 0 to 12 (mean ¼ 5.4) in the healthy group, 3 to 13 (mean ¼ 8.23) in ART-naive HIV patients, and 1 to 14 (mean ¼ 6.64) in HIV patients on ART. Statistical analysis not only demonstrated that both ART-naive HIV patients and HIV patients on ART had a higher prevalence of elevated autoantibodies than healthy controls (P < 0.05, Figure 2A ), but also revealed that HIV patients with ART-naive had a higher prevalence of elevated autoantibodies than those with ART (P < 0.05, Figure 2A ).
Higher Incidence of Individual Autoantibodies in HIV Patients
In order to understand the prevalence of a specific autoantibody in this population, the individual incidence of each autoantibody was calculated by the ratio of sample numbers with elevated autoantibody versus the total group size ( Figure 2B ). The common 32 autoantibodies did not show any elevation among all 3 groups. For the remaining 51 autoantibodies, the prevalence ranged from 0% to 20% (mean ¼ 8.24%) in healthy controls, 0% to 58.82% (mean ¼ 15.42%) in ART-naive HIV patients, and 0% to 50% (mean ¼ 13.58%) in HIV patients on ART. In summary, both ART-naive HIV patients on ART showed significantly higher incidence of specific elevated autoantibody than healthy controls (P < 0.05, Figure 2B ); ART-naive HIV patients presented with the highest prevalence of specific elevated autoantibody and was followed by HIV patients on ART. Furthermore, for the 15 specifically elevated autoantibodies, significantly higher titers and elevated frequency was observed in ART-naive HIV patients when compared to both healthy controls and HIV patients on ART (P < 0.05, Table 1 ). The microarray results established that ART-naive HIV patients had a higher incidence and higher titers of autoantibodies, and ART decreased the prevalence and titer of elevated autoantibodies per sample.
Verification of Plasma Autoantibodies Against 13 Autoantigens Using ELISA
To verify the results obtained by the microarrays, we selected 13 antigens (CENPB, Intrinsic Factor, gp210, M2, PL7, PM/Scl-75, SP100, SRP54, La/SS-B, U1-snRNP-68, U1-snRNP-A, U1-snRNP-BB 0 , and U1-snRNP-C) and performed ELISA assays. In agreement with the microarray data, the ELISA data demonstrated that 11 out of the 13 autoantibodies in ART-naive HIV patients and 5 out of the 13 in HIV patients on ART were significantly higher than the healthy controls ( Figure 2C ). Additionally, 3 of 5 autoantibodies (gp210, H2A, SP100, PM/Scl75, and SRP54) in ART-naive HIV patients were identified to be higher than those of HIV patients on ART. Although no significant difference was observed between these two HIV patients groups, the PM/ Scl-75 autoantibody in ART-naive HIV patients was significantly higher than the healthy control, while it was not increased in HIV patients on ART.
Depletion of CD33
R CD11b R Cells Remarkably Impaired the Autoreactive B Cell Response Ex Vivo B cell ELISpot was used to determine whether these autoantibodies were produced by specific autoreactive B cells in vivo. For all three groups (healthy control, HIV patients without treatment, and HIV patients on ART), B cell ELISpot assay was performed for 5 PBMCs samples ( Figure 3A-C) . In mixed autoantigen coated PVDF membrane wells, visualization of spots suggested the existence of autoantigen-specific B cells as Figure 3A indicated. The strongest autoantigen specific B cell response was observed in ART-naive HIV patient' samples, and healthy control samples had the weakest response ( Figure 3A, B) . These results were consistent with the frequency of elevated autoantibodies in these 3 groups; the maximum prevalence of elevated autoantibodies was in ART-naive HIV patients, followed by HIV patients on ART (Table 1) . Notably, healthy controls not only had a very low specific B cell response against autoantigens ( Figure 3A, B) , but also had relatively low total IgG production by B cells compared to HIV patients ( Figure 3C) , suggesting abnormal B cell activity in HIV patients.
MDSCs (originated from CD33 þ CD11b þ ) and Tregs (CD3
þ ) play critical roles in the regulation of autoimmune responses. To examine which cell types are involved in the alterations of the autoantibody profile in HIV patients, we depleted the
þ cells by FACS and performed B cell ELISpot assays on these depleted PBMCs. The depletion of CD3 þ CD4 þ CD25 þ cells had no obvious effects on the production of autoantibodies or total IgG in vitro ( Figure 3A, B) , suggesting that Tregs do not play a significant role in autoantibody production by B cells in vitro. However, the depletion of CD33 þ CD11b þ cells remarkably impaired the production of both autoantibodies and total IgG in all 3 groups as shown in Figure 3 . In order to further determine which subpopulation of CD33 
cells (mainly M-MDSCs). These cells were cocultured with CD33
þ CD11b þ cell-depleted PBMCs at indicated ratios ( Figure 3A, B) . Interestingly, we observed that the CD33 þ
CD11b
þ HLA-DR þ cells significantly promoted the production of both autoantibodies and total IgG in a dose-dependent manner, while the CD33 þ CD11b þ HLA-DR À cells had no effect ( Figure 3A-C) . These data suggest that the CD33 þ CD11b þ HLA-DR þ cells rather than the CD33 þ
þ HLA-DR À cells promote antibody production. Notably, the CD33 þ CD11b þ HLA-DR þ cells showed similar effects on increasing antibody production in both healthy controls and HIV patients, which suggests that these cells play a role in boosting B cell response.
Dramatic Elevation of CD33
R CD11b R HLA-DR
R
Cells in the Peripheral Blood of ART-Naive HIV Patients
To evaluate the correlation between the quantity of CD33 þ CD11b þ HLA-DR þ cells and the alteration of the autoantibody spectrum, we compared the frequency of M-MDSCs
in PBMCs from HIV-seropositive subjects (n ¼ 33) with healthy subjects (n ¼ 12). The CD33 þ CD11b þ HLA-DR þ cells, accounting for nearly 90% of the CD33 þ CD11b þ cell population, in ARTnaive HIV patients had a significantly higher frequency than both healthy controls and HIV patients on ART (P < 0.01), as shown in Figure 3 . For the CD33 Figure 4) . When compared to healthy controls, the frequency of both M-MDSCs and Tregs were significantly elevated in ART-naive HIV patients or HIV patients on ART, which is consistent with previous reports. 12, 18 However, no significant difference in the frequency of M-MDSCs and Tregs was noted between these two HIV patient groups (ART-naive or on ART, P > 0.05).
Correlational analysis was performed between cell frequency and the occurrence of elevated autoantibodies in the available samples (from both healthy controls and HIV patients). Notably, only the frequency of the CD33 Figure 1 , http://links.lww.com/MD/A871). Additionally, although no significant correlation between CD4 and autoantibodies was observed in ART-naive HIV patients, most patients with extremely low CD4 counts (<300 cells/mL) displayed more than 8 elevated autoantibodies (Supplement Table 1 , http://links.lww. com/MD/A871).
DISCUSSION
Autoimmunity has long been recognized to be associated with HIV infections. However, the complex nature of the mechanism of the autoimmune response in vivo, and minimal number of studies characterizing the spectrum of plasma autoantibodies in HIV patients in the presence or absence of ART implied that emerging autoantibodies in primary HIV patients is nonspecific.
1-3 Therefore, it is crucial to evaluate whether there is a specific autoantibody profile related to HIV infection. In this study, we identified emerging autoantibody profiles in respect to HIV infections from 3 observations. First, altered autoantibody profiles were observed in ART-naive HIV patients and HIV patients on ART compared to healthy controls. Fifteen autoantibodies in ART-naive HIV patients and 8 of 15 in HIV patients on ART were significantly higher than that in healthy controls. Meanwhile, 5 of 15 autoantibodies in ART-naive HIV patients were significantly higher than that of HIV patients on ART. Additionally, the highest titer of the 15 specific elevated autoantibodies was also observed in ART-naive HIV patients. This study not only characterizes the spectrum of the plasma autoantibody profile, but also reveals the possibility of ART improving the autoimmune manifestation by decreasing the titer and incidence of autoantibodies in HIV patients.
Second, autoantibodies also displayed a significantly higher incidence in HIV patients than healthy controls. Particularly, the higher incidence of 15 specific autoantibodies is 2-10/ 17 in ART-naive HIV patients and 0-4/20 in healthy controls. Statistical analysis also confirmed that these 15 specific autoantibodies had a significantly higher prevalence in HIV patients (both ART-naive patients and patients on ART) than healthy controls. Finally, autoantibody-producing B cells were confirmed by B cell ELISpot. Similar to the order of interaction of autoantibodies from the 3 groups against autoantigens, the strongest autoreactive B cell response was found in the ART-naive HIV group, followed by HIV patients on ART, and healthy controls had the weakest response. Collectively, we have established the autoantibody spectrum related to HIV infection for the first time, and our data suggest that ART improves the autoimmune response during HIV infection. Although some aspects of HIV immunopathogenesis relevant to the promotion of autoimmunity were discussed previously, the mechanisms underlying the interplay between immune dysregulation and the impact of ART may provide important insight into understanding the manifestations of autoimmunity during HIV infection. [26] [27] [28] [29] [30] [31] [32] Immune dysregulation is a hallmark of HIV infection, which may be caused by altering the frequency of function of immune cells such as T cells, B cells, and other immune cells. [27] [28] [29] [30] [31] [32] [33] [34] [35] Recent studies indicated that elevated immune regulatory cells (MDSCs and Tregs) are associated with progression of HIV/AIDS. [12] [13] [14] [15] Despite the lack of common biomarkers, MDSCs are believed to be derived from CD33 
HLA-DR
þ cells would promote the production of autoantibodies in vivo. Flow cytometry data from all participants displayed a significant increase 
þ cell frequency promotes increased production of elevated autoantibodies in ART-naive HIV patients, and ART can improve autoimmunity in HIV patients, which is at least partly due to decreased frequency of CD33 
CD11b
þ cells promotes persistent immune activation and autoimmune response, while an increased population of suppressor cells may lead to impaired T cell immunity.
In this study, we reveal that HIV infection leads to autoimmune manifestation with a specific spectrum of circulating autoantibodies, meanwhile ART may improve the autoimmune condition and alter their autoantibody spectrum by reducing the number of CD33 þ CD11b þ HLA-DR þ cells. However, a better understanding of the mechanism behind the effect of ART on the CD33 þ CD11b þ HLA-DR þ cells may provide the necessary insight for resolving the mechanism of immune dysfunction caused by HIV infection and reconstitution of the immune system in HIV patients, which requires further investigation.
